FILE - This Tuesday, July 17, 2012, file photo shows the exterior of the Merck offices in Palo Alto, Calif. Drugmaker Merck & Co. said Friday, Oct. 26, 2012 that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug. The company beat Wall Street's profit expectations and narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. (AP Photo/Paul Sakuma, File)

Associated Press
FILE - This Tuesday, July 17, 2012, file photo shows the exterior of the Merck offices in Palo Alto, Calif. Drugmaker Merck & Co. said Friday, Oct. 26, 2012 that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug. The company beat Wall Street's profit expectations and narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. (AP Photo/Paul Sakuma, File)
FILE - This Tuesday, July 17, 2012, file photo shows the exterior of the Merck offices in Palo Alto, Calif. Drugmaker Merck & Co. said Friday, Oct. 26, 2012 that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug. The company beat Wall Street's profit expectations and narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. (AP Photo/Paul Sakuma, File)
View Comments (0)